Fortress Biotech (FBIO) Acquisitions (2015 - 2023)
Fortress Biotech (FBIO) posted quarterly Acquisitions of -$5.0 million for Q1 2023, up 75.0% year-over-year from -$2.9 million in Q1 2022, and up 75.0% quarter-over-quarter from -$20.0 million in Q1 2022.
Powered by 
Analysis
Fortress Biotech (FBIO) Acquisitions (2015 - 2023) Analysis & Trends
Fortress Biotech's Acquisitions history runs 6 years deep, the most recent figure standing at -$5.0 million for Q1 2023.
- In Q1 2023, Acquisitions rose 75.0% year-over-year to -$5.0 million; the TTM figure through Jun 2024 stood at -$5.0 million (changed 0.0% YoY), while the FY2022 annual figure was -$20.0 million, changed N/A from the prior year.
- Acquisitions for Q1 2023 stood at -$5.0 million, up from -$20.0 million in the prior quarter.
- The five-year high for Acquisitions was -$5.0 million in Q1 2023, with the low at -$20.0 million in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | - |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | -5.00 Mn |
| Mar 31, 2022 | -20.00 Mn |
| Sep 30, 2017 | -19,000.00 |
| Mar 31, 2017 | 19,000.00 |
| Mar 31, 2016 | 175,000.00 |
| Dec 31, 2015 | 28,000.00 |
| Sep 30, 2015 | 22,000.00 |